Phio Pharmaceuticals股价因制造协议而飙升

英为财情

2025/07/26

Investing.com -- Phio Pharmaceuticals Corp (NASDAQ:PHIO)股价上涨26%，此前该公司宣布与一家美国制造商签订了其主要化合物PH-762的药物物质开发服务协议。该协议涵盖PH-762的分析和工艺开发以及cGMP制造，这代表着Phio针对皮肤癌的肿瘤内治疗项目的关键进展。这家临床阶段的siRNA生物制药公司目前正在为其针对皮肤鳞状细胞癌、默克尔...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券 | 轻松买卖美股港股A股/美债/ETF/Crypto/期权期货","description":"老虎证券提供多项优惠： 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","keywords":"老虎证券,老虎证券开户,老虎证券香港,老虎证券登录,老虎证券官网,香港证券开户,证券公司开户,股票开户,香港证券公司,香港证券,证券公司,股票投资,投资app,投资平台,股票买卖,股票交易平台,股票app,证券app,新手投资","social":{"ogDescription":"老虎证券提供多项优惠： 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2554909307"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2554909307\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2554909307?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-07-26 08:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2554909307","market":"hk","top_or_hot":-1,"title":"Phio Pharmaceuticals股价因制造协议而飙升","media":"英为财情","content":"<div>\n<p>Investing.com -- Phio Pharmaceuticals Corp (NASDAQ:PHIO)股价上涨26%，此前该公司宣布与一家美国制造商签订了其主要化合物PH-762的药物物质开发服务协议。\n该协议涵盖PH-762的分析和工艺开发以及cGMP制造，这代表着Phio针对皮肤癌的肿瘤内治疗项目的关键进展。这家临床阶段的siRNA生物制药公司目前正在为其针对皮肤鳞状细胞癌、默克尔...</p>\n\n<a href=\"https://cn.investing.com/news/stock-market-news/article-93CH-2903877\">网页链接</a>\n\n</div>\n","source":"investing_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Phio Pharmaceuticals股价因制造协议而飙升</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPhio Pharmaceuticals股价因制造协议而飙升\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-26 08:39 北京时间&nbsp;&nbsp;&nbsp;<a href=https://cn.investing.com/news/stock-market-news/article-93CH-2903877><strong>英为财情</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investing.com -- Phio Pharmaceuticals Corp (NASDAQ:PHIO)股价上涨26%，此前该公司宣布与一家美国制造商签订了其主要化合物PH-762的药物物质开发服务协议。\n该协议涵盖PH-762的分析和工艺开发以及cGMP制造，这代表着Phio针对皮肤癌的肿瘤内治疗项目的关键进展。这家临床阶段的siRNA生物制药公司目前正在为其针对皮肤鳞状细胞癌、默克尔...</p>\n\n<a href=\"https://cn.investing.com/news/stock-market-news/article-93CH-2903877\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://cn.investing.com/news/stock-market-news/article-93CH-2903877","article_id":"2554909307","we_media_id":null,"thumbnails":[],"rights":{"source":"investing_news","url":"https://cn.investing.com/news/stock-market-news/article-93CH-2903877","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2554909307","pubTimestamp":1753490340,"columns":[],"sourceInfo":{"source_id":"investing_news","name":"英为财情新闻"},"weMediaInfo":null,"summary":"Investing.com -- Phio Pharmaceuticals Corp 股价上涨26%，此前该公司宣布与一家美国制造商签订了其主要化合物PH-762的药物物质开发服务协议。该协议涵盖PH-762的分析和工艺开发以及cGMP制造，这代表着Phio针对皮肤癌的肿瘤内治疗项目的关键进展。Phio Pharmaceuticals专注于利用其专有的INTASYL基因沉默技术开发治疗方法，旨在消除癌症。该公司在其公告中未披露美国制造商的名称或协议的财务条款。","collect":0,"end_time":0,"defaultTopTitle":"investing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4139":"生物科技","PHIO":"Phio Pharmaceuticals"},"translate_title":"Phio Pharmaceuticals Stock Soars on Manufacturing Deal","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PHIO":1},"content_text":"Investing.com -- Phio Pharmaceuticals Corp (NASDAQ:PHIO)股价上涨26%，此前该公司宣布与一家美国制造商签订了其主要化合物PH-762的药物物质开发服务协议。\n该协议涵盖PH-762的分析和工艺开发以及cGMP制造，这代表着Phio针对皮肤癌的肿瘤内治疗项目的关键进展。这家临床阶段的siRNA生物制药公司目前正在为其针对皮肤鳞状细胞癌、默克尔细胞癌和黑色素瘤的Phase 1b剂量递增研究的第五个也是预计最后一个队列招募患者。\n\"我们很高兴能与一家以寡核苷酸化学测序质量和专业知识著称的机构合作，\"Phio总裁兼首席执行官Bitterman先生表示。\"此外，我们重视与美国本土机构合作为我们管理团队带来的战略优势。\"\nPhio Pharmaceuticals专注于利用其专有的INTASYL®基因沉默技术开发治疗方法，旨在消除癌症。这项制造协议标志着该公司推进其临床开发管线的重要里程碑。\n该公司在其公告中未披露美国制造商的名称或协议的财务条款。\n\n本文由人工智能协助翻译。更多信息，请参见我们的使用条款。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}